SC orders Centre to form panel for law on unethical pharma marketing

What exactly has the Supreme Court ordered the Union government to do, and by when must it report back?

The Supreme Court has directed the Union government to constitute an expert committee on pharmaceutical marketing practices. The committee must examine whether companies should face a statutory, legally enforceable regulatory system. It must also provide concrete recommendations rather than leave the review open-ended.

The order follows the court’s earlier directions and observations in a petition filed by the Federation of Medical and Sales Representatives’ Associations of India. The petition raised concerns about expensive gifts, foreign trips, freebies and pressure tactics used to influence doctors’ prescribing decisions.

The Centre must return to the Supreme Court with a compliance report on January 29, 2027. The government has already said that the voluntary UCPMP, 2024 is functioning satisfactorily, but separately acknowledged the need to consider a statutory regime for pharmaceutical companies. The new committee’s recommendations will therefore shape the next stage of regulation.

What is the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), and how does it attempt to regulate gifts, trips, samples and other marketing incentives?

The Uniform Code for Pharmaceutical Marketing Practices, or UCPMP, 2024 is the current framework for guiding pharmaceutical companies’ marketing conduct. It aims to make promotion more transparent and reduce incentives that could improperly affect doctors’ prescribing decisions. The Centre told the Supreme Court that the code was functioning satisfactorily.

The code tightened rules on gifts, brand reminders, physician samples and continuing medical education. It also introduced an Ethics Committee for Pharma Marketing Practice, CEO self-declarations and expenditure disclosures. These measures create records and internal accountability around promotional spending and activities.

The framework includes complaint timelines, audit and referral mechanisms, and an Apex Committee for Pharma Marketing Practice. However, it remains voluntary rather than a statute specifically governing pharmaceutical companies. The Supreme Court has now asked the government to examine whether this approach is enough or whether legally enforceable rules are needed.

How widespread is the problem according to the current regulatory record, and how many complaints has the relevant oversight committee received so far?

The Centre told the Supreme Court that the Apex Committee for Pharma Marketing Practice had received three complaints so far. This is the clearest figure in the current regulatory record, but it does not measure the total scale of unethical pharmaceutical marketing. It only records complaints received by that committee under the existing framework.

One complaint alleged that a pharmaceutical company had provided extravagant trips to around 30 doctors. The company was reprimanded for violating the UCPMP, and the list of doctors was sent to the National Medical Commission for appropriate action. This shows that the system can identify and refer alleged violations.

The article gives no broader industry-wide estimate of gifts, trips or pressure tactics. The limited complaint count is therefore evidence about the framework’s recorded caseload, not proof that the problem is rare. The government still says the separate question of statutory regulation requires examination.

Why do expensive gifts, foreign trips and high-pressure sales tactics potentially influence which medicines doctors prescribe?

Pharmaceutical marketing can potentially influence prescribing when it offers personal benefits or applies strong promotional pressure. Expensive gifts and foreign trips may create a sense of obligation or favour toward a company. High-pressure sales tactics may repeatedly push a particular product or brand to a doctor.

The petition before the Supreme Court specifically highlighted these practices as methods allegedly used to influence doctors’ choices. It also mentioned other freebies and promotional incentives. The concern is not simply that companies advertise medicines, but that personal rewards or pressure could affect professional decisions.

The article does not establish that every gift or marketing interaction changes a prescription, nor does it quantify the overall effect. It records the allegation and the regulatory concern. That concern explains why the court is examining stronger transparency, oversight and potentially legally enforceable controls on pharmaceutical marketing.

What is the difference between a voluntary code such as the UCPMP and a statutory regime backed by law?

A voluntary code sets standards that companies are expected to follow without being created as binding statutory duties. The UCPMP, 2024 is such a framework. It uses transparency, self-declarations, complaint systems and committees to encourage compliant conduct.

A statutory regime would be established through legislation or legally binding rules. It could give regulators clearer authority to impose enforceable obligations and act against violations. The article does not specify what penalties or powers a future law would contain, so those details remain for the government’s committee to recommend.

The distinction matters because the Centre has acknowledged that regulating pharmaceutical companies requires separate consideration. The existing code primarily addresses doctors through professional and statutory regulations, while pharmaceutical companies are not covered by an equivalent clear statutory framework. The court therefore wants a concrete answer on whether voluntary compliance is sufficient.

Why have the Drugs and Cosmetics Act and the Essential Commodities Act not provided a clear legal basis for regulating pharmaceutical companies' interactions with doctors?

The legal gap comes from the subject matter of the two laws. The Drugs and Cosmetics Act, 1940 principally regulates the manufacture, quality and sale of medicines. It does not clearly address how pharmaceutical companies promote products or interact with medical practitioners.

The Essential Commodities Act, 1955 deals with medicines as essential goods, including their supply, distribution and prices. Its focus is also different from promotional conduct involving doctors. Extending either law to marketing interactions raised questions about jurisdiction, implementation and legal tenability.

Together, these limits left no clear statutory basis for regulating pharmaceutical companies’ marketing relationships with medical professionals. The government explored both routes but later acknowledged that a separate examination was necessary. That is why the Supreme Court has ordered an expert committee to recommend whether a dedicated statutory mechanism should be created and what form it should take.

What could change for pharmaceutical companies, doctors and patients if the government recommends legally enforceable rules for pharmaceutical marketing?

If the government recommends a statutory regime, pharmaceutical companies could face legally binding requirements for promotional activities, spending disclosures, gifts, samples and educational programmes. Regulators could receive clearer authority to investigate complaints and act on violations. The precise duties and penalties are not yet known.

Doctors could see stronger scrutiny of relationships with pharmaceutical companies. Existing UCPMP procedures already include complaint handling, audits, referrals and disclosure mechanisms. One company was reprimanded after a complaint about extravagant trips, and information about the doctors involved was sent to the National Medical Commission.

For patients, the intended benefit would be greater confidence that medicine choices are less affected by improper incentives. However, the article does not promise a particular outcome. The Centre must first form the committee, decide whether voluntary safeguards are enough, and recommend the form of any enforceable regime to the Supreme Court.

Key Facts:

📌 The Centre must constitute an expert committee on pharmaceutical marketing regulation.

📌 The committee must return with concrete recommendations.

📌 The Supreme Court will review compliance on January 29, 2027.

📌 UCPMP, 2024 regulates gifts, samples, brand reminders and medical education.

📌 The code introduced CEO self-declarations and expenditure disclosures.

📌 An Apex Committee handles complaints, audits and referrals.

📌 The Apex Committee had received three complaints so far.